trans-racemic-tert-butyl 3-amino-4-phenylpiperidine-1-carboxylate | 1357073-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: trans-racemic-tert-butyl 3-amino-4-phenylpiperidine-1-carboxylate
• 英文别名: tert-butyl (3S,4S)-3-amino-4-phenylpiperidine-1-carboxylate
• CAS: 1357073-14-3
• 化学式: C₁₆H₂₄N₂O₂
• 分子量: 276.379
• InChiKey: BPFDKUCSVLPAQY-UONOGXRCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-Methoxybutyl)-2,2-dimethyl-3-oxo-7-(trifluoromethyl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid 、 trans-racemic-tert-butyl 3-amino-4-phenylpiperidine-1-carboxylate 以the title compound was obtained in a similar manner to Reference Example 541的产率得到tert-Butyl (3S,4S)-3-({[4-(4-methoxybutyl)-2,2-dimethyl-3-oxo-7-(trifluoromethyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-carbonyl]amino)-4-phenylpiperidine-1-carboxylate
  参考文献：
  名称：

  BICYCLIC HETEROCYCLIC DERIVATIVE

  摘要：

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]

  公开号：

  US20110190278A1

文献信息

• [EN] CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES<br/>[FR] CARBOXAMIDES AZAHÉTÉROCYCLIQUES D'AMINES CYCLIQUES
  申请人：MERCK PATENT GMBH

  公开号：WO2012016001A1

  公开（公告）日：2012-02-02

  The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  这项发明提供了根据式(I)、式(II)和式(III)制备的新型环胺氮杂杂环羧酰胺，以及它们用于治疗高增殖性疾病，如癌症的用途。
• Bicyclic heterocyclic derivative
  申请人：Nakahira Hiroyuki

  公开号：US08389511B2

  公开（公告）日：2013-03-05

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is —N(R1b)—, etc.; G2 is —CO—, etc.; G3 is —C(R1c)(R1d)—, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其作为肾素抑制剂有用。[其中R1a为卤素等；R1m为H等；G1为—N（R1b）—等；G2为—CO—等；G3为—C（R1c）（R1d）—等；G4为氧等；R1b为可选取代的C1-6烷基等；R1c和R1d独立且相同或不同，为H等；R3为H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立且相同或不同，为-A-B基团（其中A为单键等，B为H等）等；n为1等。]
• SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF
  申请人：ZHEJIANG UNIVERSITY

  公开号：US20170107213A1

  公开（公告）日：2017-04-20

  Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (I) as AKT inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of R1, R2, R3, R4, R5, R6, ring A, ring C, B, Q, Y, Z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to AKT kinase.